PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8930576-4 1996 The substrates and inhibitors of CYP2C19 and CYP3A4 and the known genetic polymorphism of CYP2C19 explain some but not all of the interactions of lansoprazole, and particularly the interactions of omeprazole with carbamazepine, diazepam, phenytoin and theophylline or caffeine. Theophylline 252-264 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 45-51 32657910-9 2020 The final model of theophylline clearance was as follows: CL/F (L/hr/kg) = 0.0484 x 1.40 x 0.861 x 0.889 x 0.557.Smoking is a well-known factor that markedly enhances CL/F through the induction of CYP1A enzymes, whereas CAM has been reported to inhibit CYP3A4. Theophylline 19-31 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 253-259 29063606-5 2018 Although CP studies are limited, meta-analysis-based reduction in CYP1A2, CYP2C19, and CYP3A4 enzyme abundances in a virtual oncology population effectively captures CP-PK for caffeine, theophylline, midazolam, simvastatin, omeprazole, and a subset of oncology compounds. Theophylline 186-198 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 87-93 11408986-7 2001 This case indicates that levofloxacin and clarithromycin inhibited theophylline metabolic pathways catalyzed by both CYP1A2 and CYP3A4 and resulted in the decrease in theophylline clearance. Theophylline 67-79 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 128-134 11408986-7 2001 This case indicates that levofloxacin and clarithromycin inhibited theophylline metabolic pathways catalyzed by both CYP1A2 and CYP3A4 and resulted in the decrease in theophylline clearance. Theophylline 167-179 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 128-134 9447218-3 1998 CYP3A4 and CYP1A2 enzymes are involved in drug interactions involving theophylline. Theophylline 70-82 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 30762305-1 2019 This study provides whole-body physiologically-based pharmacokinetic models of the strong index cytochrome P450 (CYP)1A2 inhibitor and moderate CYP3A4 inhibitor fluvoxamine and of the sensitive CYP1A2 substrate theophylline. Theophylline 211-223 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 144-150 7619673-12 1995 The results suggest that inter-individual variability in the inhibition of theophylline metabolism by ciprofloxacin can be attributed to inter-individual differences in the level of CYP1A2 expression and/or in the degree of inhibition of hepatic CYP1A2 and CYP3A4. Theophylline 75-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 257-263